Search Results
1
Study Matches
Site for A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients with Moderate to Severe Hidradenitis Suppurativa (HS)
Moderate to Severe Hidradenitis Suppurativa (HS): Placebo-Controlled (non active ingredient), 12-week treatment period.
Oral medicine taken twice daily. Males/Females 18 - 70 years of age.
The goal of the study is assess the efficacy (desired or intended result) of ATI-450 in patients with moderate to severe HS
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-1513
All
18 year(s) or older
N/A
Skin Conditions